Figure 9. Potency assessment of the confirmed antagonist vincristine.

Dose response in absence of resveratrol or with 30 or 80 µM resveratrol co-treatment toward four cancer cell lines in an Alamar Blue-based viability assay. Dose response curves of vincristine toward A) human hematopoietic cancer cell line HL-60/RV+ (IC₅₀ = 3.1, greater than 100 µM and greater than 100 µM in absence of resveratrol or with 30 or 80 µM resveratrol co-treatment) B) human uveal melanoma cell line OCM290 (IC₅₀ = 0.040, greater than 100 µM and greater than 100 µM in absence of resveratrol or with 30 or 80 µM resveratrol co-treatment) C) triple negative human breast cancer cell line MDA-MB-231 (IC₅₀ = greater than 100, greater than 100 µM and greater than 100 µM in absence of resveratrol or with 30 or 80 µM resveratrol co-treatment) and D) human retinoblastoma cell line NCC-RbC-60 (IC₅₀ = 0.010, greater than 100 µM and 1.7 µM in absence of resveratrol or with 30 or 80 µM resveratrol co-treatment). For partial dose response curves leading to a maximum of 50% inhibition or less, an IC₅₀ greater than 100 µM was reported, since an accurate IC₅₀ cannot be calculated.